Insufficient sleep predicts poor weight loss maintenance after 1 year.

Bogh AF, Jensen SBK, Juhl CR, Janus C, Sandsdal RM, Lundgren JR, Noer MH, Vu NQ, Fiorenza M, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS

Sleep1 May 2023Cited by 16 (Europe PMC)

PMID36472579PMCIDPMC10171640DOI10.1093/sleep/zsac295PepBankPUB-36472579

Read at source PubMedAsk about this study

Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity during weight loss maintenance, liraglutide increased sleep duration compared with placebo after 26 weeks.
In plain wordsIn adults with obesity keeping weight off, liraglutide users slept longer than placebo users after 26 weeks.
Peptide
Liraglutide
Outcome
IncreaseSleep duration at 26 weeks
Study
n = 195
Comparator
Placebo
Outcome group
Sleep · Sleep
Studied dose
3.0 mg/day · 1 yearAs given in this study (human).
Measurements
Sleep duration change
5 min/night
liraglutide
Sleep duration change
−15 min/night
placebo
Source sentences
Summary
During the weight maintenance phase, participants undergoing liraglutide treatment displayed increased sleep duration compared with placebo after 26 weeks (5 vs. -15 min/night) but not after 1 year.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, controlled, two-by-two factorial study, 195 adults with obesity completed an 8-week low-calorie diet and were randomly assigned to 1-year weight loss maintenance with or without exercise and liraglutide 3.0 mg/day or placebo.
Report a problemFND-3647257901
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity during weight loss maintenance, liraglutide did not increase sleep duration compared with placebo after 1 year.
In plain wordsIn adults with obesity keeping weight off, liraglutide users did not sleep longer than placebo users after 1 year.
Peptide
Liraglutide
Outcome
No significant changeSleep duration at 1 year
Study
n = 195
Comparator
Placebo
Outcome group
Sleep · Sleep
Studied dose
3.0 mg/day · 1 yearAs given in this study (human).
Source sentences
Summary
During the weight maintenance phase, participants undergoing liraglutide treatment displayed increased sleep duration compared with placebo after 26 weeks (5 vs. -15 min/night) but not after 1 year.
1 context sentence(design, population, supporting numbers)
Summary · context
In a randomized, controlled, two-by-two factorial study, 195 adults with obesity completed an 8-week low-calorie diet and were randomly assigned to 1-year weight loss maintenance with or without exercise and liraglutide 3.0 mg/day or placebo.
Report a problemFND-3647257902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT04122716

Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet

Signe Torekovn = 215Sept 2016 to est. Nov 2021

Obesity

Trial page ClinicalTrials.govUpdated 2 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.